Pfizer

Pfizer Makes Another Recall

Pfizer is reported to have widened the voluntary recall of its blockbuster cholesterol-fighting drug again. As per the company’s statement, an additional 38,000 bottles of the drug Lipitor have been recalled.

The decision emerged following reports that linked a "moldy or musty" odor with the packaging bottles, the Company highlighted. Pfizer had earlier given a recall for over 190,000 bottles of Lipitor because of similar kind of complaints.

General: 
Companies: 

Non-prescription Drugs no Cure for Chronic Pain

In line with the Asian Pacific Digestive Week , a survey, initiated by the biopharmaceutical firm Pfizer and conducted in China, Taiwan and Thailand, shows that patients that suffer from chronic pain prefer self-medication as a treatment over consulting medical advice.

About 60% out of the 1,220 surveyed patients who all have chronic disease conditions report that they ease and control their pain with non-prescription drugs from the store next door.

Companies: 
General: 

Pfizer Linked With Health Issues

A novel study conducted by German researchers unveiled Wednesday claimed the Pfizer's antidepressant reboxetine as completely ineffective and detrimental for the patient. It highlighted that the health risks associated with the drug outpaces the benefits.

The drug, reboxetine, which is retailed in UK under the label Edronax, poses no bigger results than a placebo, or dummy pill, claimed researchers from the German Institute for Quality and Efficiency in Health Care (IQWiG).

Companies: 
General: 

Pfizer Linked With Health Issues

A novel study conducted by German researchers unveiled Wednesday claimed the Pfizer's antidepressant reboxetine as completely ineffective and detrimental for the patient. It highlighted that the health risks associated with the drug outpaces the benefits.

The drug, reboxetine, which is retailed in UK under the label Edronax, poses no bigger results than a placebo, or dummy pill, claimed researchers from the German Institute for Quality and Efficiency in Health Care (IQWiG).

Companies: 

Cancer Drug Mylotarg to Be Withdrawn by Pfizer

The Food and Drug Administration said on Monday that Pfizer Inc. is withdrawing its cancer drug Mylotarg from the U. S. market after a clinical trial depicted that the drug wasn't effectual and had more safety troubles.

Mylotarg, which is marketed by Wyeth until Pfizer purchased the Company in the previous year, was given approval in the year 2000 as part of FDA's accelerated- approval program.

The drug was given approval for patients aged 60 and above suffering a type of severe myeloid leukemia, which is a type of a bone-marrow cancer.

Companies: 

Pages

Subscribe to RSS - Pfizer